Trial Profile
Phase 2 Study of Abemaciclib (LY2835219) in Dedifferentiated Liposarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Sep 2023
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary)
- Indications Liposarcoma
- Focus Therapeutic Use
- 11 Sep 2023 Results(n=30) published in the Clinical Cancer Research.
- 18 Aug 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 18 Aug 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.